Breast and prostate cancers are among the most common of all cancers. They are referred to as hormone-dependent cancers, because estrogen and androgen are involved in their development and growth. The effects of these hormones are mediated by their respective receptors, estrogen receptor (ER) a and androgen receptor. Around 18 years ago, a second ER, ERb, which has a very similar structure to ERa, was discovered. Its function has been investigated using a variety of methods and biological systems, leading to our present understanding that ERb can interact with or inhibit ERa and androgen receptor function directly and ⁄ or indirectly, suppress cell growth, and influence responsiveness to endocrine therapy. In order to apply the "inhibition of cell growth" function to cancer treatment, several specific ERb agonists have been synthesized and are being tested for effectiveness in cancer treatment. We need to keep our eyes on ERb.
Breast and prostate cancers are among the most common of all cancers. They are referred to as hormone-dependent cancers, because estrogen and androgen are involved in their development and growth. The effects of these hormones are mediated by their respective receptors, estrogen receptor (ER) a and androgen receptor. Around 18 years ago, a second ER, ERb, which has a very similar structure to ERa, was discovered. Its function has been investigated using a variety of methods and biological systems, leading to our present understanding that ERb can interact with or inhibit ERa and androgen receptor function directly and ⁄ or indirectly, suppress cell growth, and influence responsiveness to endocrine therapy. In order to apply the "inhibition of cell growth" function to cancer treatment, several specific ERb agonists have been synthesized and are being tested for effectiveness in cancer treatment. We need to keep our eyes on ERb.
Etiology of Breast Cancer and Prostate Cancer
B reast cancer is the most threatening neoplastic disease in females; nearly 1.7 million women per year are diagnosed with it, accounting for 25% of all cancers in females worldwide. Prostate cancer is the second most frequently occurring cancer in males, with approximately 1.1 million new diagnoses per year (World Cancer Research Fund International, http:// www.wcrf.org). These two leading cancers are so-called "hormone-dependent cancers", which means that these cancers are initiated and developed by sex steroid hormones, that is, estrogens and androgens.
Androgen and AR, Estrogen and ER
Androgens include adrenal androgens and testosterone. Adrenal androgens are synthesized by the adrenal cortex and testosterone is produced in the testicles of males and the ovaries of females. 5a-Dihydrotestosterone is the most potent ligand of AR and is converted from testosterone in target tissues like prostate; it is processed for excretion by hydroxylation. One hydroxylation product, 3bAdiol, has been reported as the most likely ligand of ERb in the prostate (Fig. 1) . (1, 2) Androgens are precursors of estrogens and therefore very important for ERs. Estrogens are synthesized by aromatization of androgens.
The most potent ligand of ER is E2, which is synthesized from either estrone or testosterone (Fig. 1) .
Both ER and AR belong to the nuclear receptor superfamily, which is composed of transcriptional factors, regulated by ligand binding. As a result of ligand binding these receptors bind to specific DNA sequences, either ERE (3) or androgen response element, in their target genes, and recruit transcription factors, resulting in hormone-stimulated transcription (Fig. 2a) .
Two forms of ER: ERa and ERb
The first estrogen receptor, ERa, was cloned from the MCF-7 human breast cancer cell line in 1985, (4) and the second estrogen receptor, ERb, was discovered in rat prostate in 1996. (5) Estrogen receptor a is expressed mainly in sex organs, that is, breast, uterus, ovary, testis, and epididymis, but also in other organs, for example, liver, kidney, adrenal glands, pituitary gland, and hypothalamus. Expression of ERb is not predominantly in sex organs except prostate; it is found in skin, bone, brain, lung, urinary bladder, blood vessels, lymphocytes, and fat tissues and appears to be widely distributed throughout the whole body. (5) The structure of ERb is homologous to that of ERa. The DNA-binding domain of ERb is 96% conserved compared to ERa, and the ligand-binding domain shows 58% conserved residues, (5) suggesting that while ERb could bind the same target genes as ERa, it might have different specific ligands (Fig. 2) . With E2 bound, helix 12 of the receptor is exposed and binds cofactor proteins, but with other ligands, different cofactors may be recruited, leading to activation of different downstream genes.
Estrogen receptor has been shown to bind to AP1 or specificity protein 1 (6) without dimerization, (7) and thus can activate downstream target genes without EREs. E2 activates transcription on AP1 site with ERa; however, it inhibits transcription with ERb. It suggested that ERa and ERb have opposite transcriptional effects at AP1 sites when complexed with E2. (8, 9) Estrogen receptor b variants. Multiple variant forms of ERb were detected in 1998. (10) The most significant form was named ERb2 (or ERbcx). Estrogen receptor b2 was cloned as full-length cDNA and had identical DNA binding domains, however, its ligand affinity is apparently different. In rodents, an ERb isoform named ERbins has been described which contains a 54-nt insertion in the ligand-binding domain and shows reduced affinity for estrogens. (11, 12) ERb2 and ERbins are different forms but might have the same function in different species.
Both ERa and ERb1 require ligand binding, and ERb1 can form homodimers as well as ERa-ERb1 heterodimers on ERE. However, ERb2 was found to form heterodimers with ERa or ERb1 without ligand binding (10, 13) and inhibit ERE binding of ERb1 or ERa (Fig. 2b) . Therefore, ERb2 is functional modulators of ERa and ERb1.
Estrogen receptor b has a somewhat lower E2 binding affinity than ERa: the Kd values of E2 calculated from saturation curves are 0.06 nM for ERa and 0.24 nM for ERb. (5) Estrogen receptor b can bind other ligands with rather higher affinity than ERa, for example, 4-hydroxytamoxifen, the phytoestrogen genistein, and, testosterone derivatives, 3bAdiol.
Estrogen Receptor in the Breast
In the mammary glands, both ERa and ERb are present. Expression of ERa is limited to luminal cells but ERb is widely distributed, in both basal and luminal epithelial cells, fibroblasts, adipose cells, lymphocytes, and endothelial cells (Fig. 3) . (14) (15) (16) Estrogen receptor a is the principal receptor for estrogen function in the breast. Estrogen is essential for homeostasis of normal mammary gland, however, activation of ERa results in induction of cell cycling and stimulation of cell growth, and can result in the initiation and development of cancer. Clinically, evaluation of ERa expression in breast cancer specimens is considered essential for the choice of treatment, however, response to hormone therapy cannot be exactly predicted by ERa status.
Function of ERb in the Breast
Molecular biological studies. In the MCF-7 breast cancer cell line, estradiol increases cell proliferation and causes the cells to form tumors in a mouse xenograft model, however, introducing ERb into MCF-7 cells causes a reduction of Fig. 1 . Steroid synthesis in key organs and steroid receptors in prostate and breast. Androgen, precursor estrogen, and testosterone are produced in the adrenal cortex. Androgen is converted into testosterone in testis or ovary and further converted into dihydrotestosterone (DHT) in prostate or into estrogen in ovary and peripheral fat tissue. Estrogen receptor b (ERb) is present in both prostate and breast, however, its ligand seems to be estrogen in breast and 5a-androstane-3b, 17b-diol (3bAdiol) in prostate. AR, androgen receptor. proliferation in vitro and prevents tumor formation in response to estradiol. (17) Another cell model with constitutive expression of ERb resulted in a significant inhibition of cellular growth compared with the mock transfected and prevented establishment and growth of tumors as s.c. xenografts in immunodeficient mice. (18) The other xenograft model using the ERapositive breast cancer cell line T-47D in which ERb expression was controlled through the Tet-off system also showed that ERb reduced tumor growth by decreasing expression of vascular endothelial growth factor and platelet-derived growth factor b. (19) The mechanism of growth inhibition was reported to be a retardation of transition into the S-phase of the cell cycle, (18) and reduced cyclin D1 expression, frequently leading to G 1 arrest. (20) Microarray analysis in ERb stably transfected T-47D cells showed that ERb overexpression specifically downregulated major DNA replication and cell cycle-related genes. (21) In MCF-7 cells, ERb was found to inhibit proliferation by repressing c-myc, cyclin D1, and cyclin A gene transcription, and increasing the expression of p21 and p27, leading to G (2) cell cycle arrest (Fig. 4a) . (17) Animal studies. A study using rat mammary glands revealed that ERb was expressed in 60-70% of cells at all stages of development, however, 90% of ERb-expressing cells did not express proliferation markers. (22) The generation of BERKO mice has revealed that mammary gland development, for example, ductal elongation and lobular formation, is the same in BERKO and wild-type mice. (14) However, BERKO shows reduced levels of adhesion molecules, that is, E-cadherin, connexin 32, occludin, and integrin a2 (Fig. 4b) , and increased cell proliferation, indicating a role for ERb in the final terminal differentiation of the mammary gland. (23) Clinical studies. Many studies have examined the association of ERb mRNA or protein expression with clinical parameters of breast cancer. Although this is still a matter of controversy, most reports have shown that higher expression of ERb1 is significantly correlated with good prognosis, and expression tends to decrease during progression. (24) (25) (26) (27) Estrogen receptor b agonist was reported to prevent ductal carcinoma in situ from invasive change. (27) A multivariate analysis of 442 invasive breast cancers with adjuvant tamoxifen revealed that ERb1 status emerged as an independent predictor of recurrence and mortality, especially in a population with triple negative cancers. (26) In several studies on its interaction with tamoxifen, higher ERb expression was an independent predictor of better response. (26, 28, 29) Overexpression of ERb1 was also associated with increased sensitivity to 4-hydroxytamoxifen. (30) A study of ERa-positive breast cancer patients who had been treated with neoadjuvant hormone therapy found that ERb mRNA was neither independently predictive of response to preoperative toremifene nor improved predictions based on ERa mRNA levels, which are positively correlated with response. (31) Estrogen Receptor b2
From a clinical point of view, it would be interesting if ERb2 could affect the sensitivity to hormone treatment of ERa-positive breast cancer. There have been several reports about the relationship between ERb2 and tamoxifen treatment but the results are conflicting. For example, ERb2 protein expression was reported to be a good predictive marker for endocrine therapy, (32) and ERb2 mRNA to be independently predictive of tamoxifen treatment outcome in ERa-positive tumors, (33) but a more detailed study suggested that expression of ERb2 in primary lesions correlated with a poor response to tamoxifen, especially in cancers with a low Allred score for progesterone receptor. (34) In summary, ERb1 or ERb2 appear to interfere with ERa function and downregulate ERa downstream genes. Therefore, the presence of ERb1 or ERb2 could affect the sensitivity to drugs that directly bind ERa, that is, tamoxifen or raloxifene.
Estrogen Receptors in the Prostate
As a male sex-accessory tissue, the prostate has been regarded as androgen-regulated, with AR considered as the hormone receptor responsible for the regulation of prostatic growth. Testosterone is produced in and secreted by the testis and is converted into DHT in androgen-responsive tissue such as the prostate and it elicits cell growth and proliferation as well as cancer development. Therefore, a traditional therapy for prostate cancer has been androgen ablation, by castration, administration of estrogenic agents like diethylstilbestrol to suppress androgen production indirectly by the hypothalamo-pituitarygonadal axis, use of gonadotropin-releasing hormone agonists to downregulate the pituitary or use of AR antagonists. Estrogen receptor a exists in stroma and is very important for prostate development, (38) and it appears in ductal epithelial cells in very short time when it is necessary for ductal branching. (39) However, it is rarely present in the adult prostate, in which ERb is the most abundant ER. The latter is strongly expressed in the basal and secretory compartments of benign prostate epithelium as well as in the stroma and the infiltrating immune cells. (40) (41) (42) Association of ERa and ERb in human prostate cancer. Estrogen receptor b exists in some prostate cancer cell lines, but not ERa. (43) Using an adenoviral delivery system to induce ERb expression in prostatic cancer cells, it was shown that ERb has antiproliferative, anti-invasive, and pro-apoptotic effects. (44) Another study, using xenografts of ERb-expressing LNCap prostate cancer cells, showed that E2 treatment inhibited tumor establishment and growth. (45) Experiments using stably transfected ERb1 or ERb2 in prostate cancer cell lines revealed that ERb1 inhibits proliferation, whereas ERb2 increases proliferation, therefore, ERb2 is oncogenic but ERb1 has tumor-suppressing effects. (46) Intensive investigation of the expression of ERs, especially ERb and its variants, in human prostate and prostatic diseases, such as hyperplasia and prostate cancer, has shown that ERb expression declines during hyperplastic changes (40, 47, 48) and ERb1 is lost during cancer progression, whereas its splice variant, ERb2, is expressed in advanced prostate cancer. (46, 49) An association between a single nucleotide polymorphism located in the promoter region of the ERb gene and risk of developing prostate cancer was shown in a large populationbased case-control study. (50) This evidence highly suggested antiproliferative effects of ERb. It has been suggested that the two ERs play opposing roles in prostate cancer: that ERa is oncogenic and promotes cell proliferation and survival, whereas ERb is predominantly protective, being anticarcinogenic and pro-apoptotic. (51) (52) (53) (54) (55) Expression of ERa has also been observed in prostate cancer, however, it was located in stromal cells. Therefore, a model in knockout mice was investigated to clarify the function of ERs.
Animal models. BERKO mice show high proliferation and high apoptosis in the epithelial cells of the ventral prostate (56, 57) and increased prostatic hyperplasia, (56, 58) indicating that ERb1 is important for maintaining a normal prostate and for suppressing tumor growth. Activation of ERa in BERKO mice leads to aberrant proliferation, inflammation, and the development of premalignant lesions; in contrast, activation of ERb in ERKO mice is critical in prostatic stromal-epithelial cell signaling and mediating antiproliferative effects that balance the proliferative action of androgens on the epithelium. (59) In another experiment, diethylstilbestrol treatment in ERKO or BERKO mice induced prostatic squamous metaplasia in WT and BERKO mice, but not in ERKO mice. (60) Administration of testosterone and estrogen together to BERKO or ERKO mice showed that WT and BERKO mice developed prostatic intraepithelial neoplasia, whereas ERKO mice did not.
Aromatase knockout mice, which lack synthesis of estrogen, is a good model to evaluate the effect of endogenous estrogen. ArKO mice had reduced incidences of hyperplastic lesions. (61) A selective ERb agonist induces apoptosis in ArKO mouse prostate. (62) All of these investigations showed that BERKO, which is lacking ERb, developed induced proliferation and hyperplastic lesion in its prostate, whereas ERKO, which is lacking ERa, did not, indicating that estrogenic action to stimulate prostatic disease is ERa responsive and, in contrast, ERb is a guard to protect prostatic disease.
Studies of CYP7B1 and 3bAdiol. In the prostate, the most abundant estrogen is not E2 but 3bAdiol. (2) The enzyme CYP7B1 is responsible for the hydroxylation of 3bAdiol to Triol for excretion from the body.
Mice in which CYP7B1 has been knocked out have increased concentrations of 3bAdiol in tissues where there is DHT, like prostate. Decreased proliferation of ventral prostate epithelial cells has been observed in CYP7B1 knockout mice, which is attributed to activation of ERb by 3bAdiol. (2) Treatment of the prostate cancer cell line PC3 with 3bAdiol induces a broad range of antitumor changes, including decreased proliferation, increased cell adhesion, and reduced cell migration and invasive capabilities in vitro. (63) Estrogen receptor b-mediated inhibition of cell migration by 3bAdiol was also observed in the prostate cancer cell line DU145. (64) 
Conclusions and Future Perspectives
It has been widely reported that incidence of both breast and prostate cancer are higher in Western populations than Asian. One possible explanation for this phenomenon is diet. Soybean products contain phytoestrogens, which are very good activating ligands of ERb. One such compound, genistein, was found to reduce the potential for neoplastic transformation in breast and prostate tissues; (65, 66) similar results were obtained with other isoflavones. (67) In addition, several ERb-selective agonists have been synthesized (68) and used to examine the effect of ERb stimulation. Treatment of the prostate cancer cell line DU145 with one such agonist, diarylpropionitrile, decreased cell proliferation. (69) Diarylpropionitrile also prevented the development of prostatic hyperplasia and inflammation in testosterone-treated luteinizing hormone receptor knockout mice, which were lacking postnatal androgen production. (70) Another ERb selective agonist, 8b-VE2, was shown to reverse the hyperplasia observed in the prostates of ArKO mice and induced cell death in benign prostate hypertrophy and prostate cancer. (71) Another novel selective ERb agonist, SERBA-1, was also reported to show beneficial effects in a benign prostate hypertrophy model. (68) New therapies targeting ERb seem promising.
During endocrine therapy, many cancers acquire resistance against these therapies, for example, anti-estrogen, tamoxifen, or aromatase inhibitor resistance in breast cancer and antiandrogen or flutamide in prostate cancer. Estrogen receptor b-targeting therapy can be different from ERa or AR, as ERb needs to be stimulated whereas ERa or AR need to be inhibited. However, acquisition of resistance is the main problem during hormone treatment of hormone-dependent cancer. Mechanisms of acquisition are under investigation by gene expression analysis and some clues to close this phenomenon were revealed. One is activation of cell growth signaling other than the estrogen-ER or androgen-AR pathways, for example, the PI3K ⁄ Akt ⁄ mTOR pathways. (72, 73) Therefore, targeting inhibition of PI3K ⁄ Akt ⁄ mTOR pathways is applied to patients with hormone receptor-positive advanced breast cancer (74, 75) and showed prolongation of progression-free survival. (76) Estrogen receptor b is the frontier of nuclear receptor transcriptional factor, which has high potential to be a target of cancer treatment. To succeed in applying ERb-targeting therapy to breast and prostate cancer, there must be more knowledge of ERa or AR. Further investigation is still awaited.
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